SEC Contract Filing

Filing Date: 2023-04-07

Document Content:
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>3
<FILENAME>txmd-ex1045_158.htm
<DESCRIPTION>EX-10.45
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
txmd-ex1045_158.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.45</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-weight:bold;font-size:11pt;font-family:Sabon;font-style:normal;text-transform:none;font-variant: normal;">[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(2). SUCH EXCLUDED INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:11pt;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">AMENDMENT No. 1</font></p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">to the License Agreement</font></p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">between Mayne Pharma LLC and TherapeuticsMD, Inc. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:70.2%;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk119749273"></a>This Amendment No. 1 (&#8220;<font style="font-weight:bold;">Amendment</font>&#8221;) is entered into as of December 30, 2022<font style="font-weight:bold;"> </font>(&#8220;<font style="font-weight:bold;">Amendment Effective Date</font>&#8221;) by and between Mayne Pharma LLC, a limited liability company formed under the laws of Delaware and located at 3301 Benson Drive Suite 401, Raleigh NC 27609 (&#8220;<font style="font-weight:bold;">Mayne</font><a name="_Hlk119749273"></a>&#8221;), and TherapeuticsMD, Inc., a corporation formed under the laws of Nevada and located at 951 Yamato Road, Suite 220, Boca Raton, Florida 33431 (&#8220;<font style="font-weight:bold;">TXMD</font>&#8221;). TXMD and Mayne are each referred to individually as a &#8220;<font style="font-weight:bold;">Party</font>&#8221; and together as the &#8220;<font style="font-weight:bold;">Parties</font>.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:10.8%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Mayne and TXMD are parties to a License Agreement dated as of December 4, 2022 (the &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;), concerning the development and commercialization of the Licensed IP; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:10.8%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties mutually desire to amend, modify and restate certain terms and conditions of the Agreement regarding the Parties&#8217; pharmacovigilance obligations and payment of certain royalties;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:10.8%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.11%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Sabon;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="text-transform:none;color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;text-transform:none;color:#000000;">DEFINITIONS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.11%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise defined herein, capitalized w